Characteristics | Duloxetine, n = 239 | Placebo, n = 248 |
---|---|---|
Age, yrs, mean (SD) | 62.7 (9.17) | 62.2 (9.23) |
Sex, female, n (%) | 159 (66.5) | 188 (75.8) |
Origin, n (%) | ||
White | 220 (92.1) | 224 (90.3) |
Hispanic | 11 (4.6) | 10 (4.0) |
African American | 6 (2.5) | 9 (3.6) |
East Asian | 0 (0) | 4 (1.6) |
Native American | 2 (0.8) | 1 (0.4) |
NSAID use, n (%) | 105 (43.9) | 112 (45.2) |
Duration of OA since diagnosis, yrs, mean (SD) | 6.52 (7.15) | 6.33 (6.73) |
Duration of OA pain since onset, yrs, mean (SD) | 8.56 (8.16) | 7.98 (7.54) |
WOMAC physical function subscale, mean (SD) [range] | ||
Total score (normalized to 0–100) | 52.6 (16.0) [8–100] | 54.4 (13.7) [4–84] |
Pain score* (normalized to 0–100) | 52.7 (14.7) [15–100] | 53.0 (14.3) [10–85] |
Stiffness score (normalized to 0–100) | 55.8 (18.6) [0–100] | 57.9 (18.9) [0–100] |
Physical Function score** (normalized to 0–100) | 54.0 (15.5) [4–100] | 55.2 (13.5) [4–85] |
BPI average pain score, mean (SD) [range] | 6.11 (1.48) [3–10] | 6.18 (1.40) [2–10] |
CGI-Severity, mean (SD)† [range] | 3.04 (1.41) [1–6] | 2.98 (1.44) [1–6] |
↵* Duloxetine group, n = 239; placebo group, n = 247.
↵** Duloxetine group, n = 231; placebo group, n = 245.
↵† Duloxetine group, n = 235; placebo group, n = 248. BPI: Brief pain Inventory; CGI: clinical global impression; NSAID: nonsteroidal antiinflammatory drug; OA: osteoarthritis; WOMAC: Western Ontario and McMaster Universities Osteoarthritis index.